Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update

BRANFORD, Conn., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced financial results for the third quarter ended September 30, 2026.

Press Release Highlights * Reported third quarter 2026 revenue of $212,000 during the transition period from Platinum® to Proteus, which is expected to continue through the first half of 2027 * Highlighted interim Proteus performance data presented at World HUPO including approximately 30 times more sequencing output per chamber in a controlled peptide study * Highlighted detection of 19 amino acids, with the 20th expected before year-end * Announced launch of the Proteus pre-order program * Updated full-year 2026 guidance for lower adjusted total operating expenses and lower total cash usage, and reaffirmed cash runway into the fourth quarter of 2028 “We made significant progress during the third quarter as we continued to advance Proteus toward commercial launch,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “Based on recent performance data, we believe we have substantially addressed the instrument variability issues identified earlier in development, and design activities for our additional instrument cycle are now complete. During the quarter, we also advanced recognizer development to 19 amino acids, keeping us on track to achieve all 20 amino acids by year-end. We also made meaningful progress in our library preparation technology development and accelerated the integration of AI throughout our data analysis pipeline. Together, these advancements continue to strengthen the capabilities of the Proteus platform and our confidence in its commercial potential.”